A Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas (Axi-STS)
A Clinicopathological Phase II Study of Axitinib in Patients With Advanced Angiosarcoma and Other Soft Tissue Sarcomas
Sponsor: Cancer Research UK
Listed as NCT01140737, this PHASE2 trial focuses on Soft Tissue Sarcoma and remains completed. Sponsored by Cancer Research UK, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Jan 2021 — Apr 2021 [monthly]
Unknown Status PHASE2
▶ Show 4 earlier versions
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Oct 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Aug 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cancer Research UK
- Pfizer
- Sheffield Teaching Hospitals NHS Foundation Trust
- University of Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom , Bristol, United Kingdom , Edinburgh, United Kingdom , Leeds, United Kingdom , London, United Kingdom , Manchester, United Kingdom , Metropolitan Borough of Wirral, United Kingdom , Nottingham, United Kingdom , Oxford, United Kingdom , Sheffield, United Kingdom and 1 more location